Provista Diagnostics
Todos Medical Subsidiary Inks US Commercialization Deal for Acumen Diagnostics Sepsis PCR Test
Todos Medical acquired the subsidiary, Provista Diagnostics, in early 2021 from Ascenda Biosciences for $7.5 million in cash and stock.
The company has also joined the Cancer Moonshot program, working within its Blood Profiling Atlas Project on pre-analytical variation in molecular tests.
The company is expanding test availability from its initial clinical study partners while preparing to launch clinical utility and health economic studies.
The customizable, programmable antibody array has the proteins synthesized on it from cDNA and looks at a broader range of HPV subtypes than ever before.
Provista Closes $5.25M Financing
The firm plans to use the money to commercially develop its proteomic diagnostics, as well as for management hires and general corporate purposes.
Aug 4, 2015
Provista Dx Raises $6M
Mar 17, 2015
Provista Dx Raises $3.9M
Jun 26, 2014